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Amyloid deposition of WT human 2-microglobulin (WT-
h2m) in the joints of long-term hemodialysis patients is the
hallmark of dialysis-related amyloidosis. In vitro, WT-h2m
does not form amyloid fibrils at physiological pH and tempera-
ture unless co-solvents or other reagents are added. Therefore,
understanding how fibril formation is initiated and maintained
in the joint space is important for elucidating WT-h2m aggre-
gation and dialysis-related amyloidosis onset. Here, we investi-
gated the roles of collagen I and the commonly administered
anticoagulant, low-molecular-weight (LMW) heparin, in the
initiation and subsequent aggregation phases of WT-h2m in
physiologically relevant conditions. Using thioflavin T fluores-
cence to study the kinetics of amyloid formation, we analyzed
how these two agents affect specific stages of WT-h2m assem-
bly. Our results revealed that LMW-heparin strongly promotes
WT-h2m fibrillogenesis during all stages of aggregation. How-
ever, collagen I affected WT-h2m amyloid formation in con-
trasting ways: decreasing the lag time of fibril formation in the
presence of LMW-heparin and slowing the rate at higher con-
centrations. We found that in self-seeded reactions, interaction
of collagen I with WT-h2m amyloid fibrils attenuates surface-
mediated growth of WT-h2m fibrils, demonstrating a key role
of secondary nucleation in WT-h2m amyloid formation. Inter-
estingly, collagen I fibrils did not suppress surface-mediated
assembly of WT-h2m monomers when cross-seeded with
fibrils formed from the N-terminally truncated variant N6-
h2m. Together, these results provide detailed insights into how
collagen I and LMW-heparin impact different stages in the
aggregation of WT-h2m into amyloid, which lead to dramatic
effects on the time course of assembly.
Dialysis-related amyloidosis (DRA)5 is a severe condition
that leads to progressive bone and joint atrophy in the majority
of long-term hemodialysis patients (1–5). This disorder results
from the deposition of amyloid plaques formed predominantly
of WT human 2-microglobulin (WT-h2m) in joints and car-
tilage tissue (3, 6 – 8). In its nonpathogenic role, WT-h2m con-
stitutes the light chain of the major histocompatibility complex
class I, which functions in presenting antigens to T-cells (9).
After dissociation from the major histocompatibility complex
class I complex, WT-h2m is normally degraded and excreted
by the kidneys (10). In renal failure, the concentration of 2m in
the plasma is increased up to 60 times compared with that of
healthy individuals (3, 6 – 8). Aggregation of WT-h2m then
leads to the formation of amyloid plaques that are deposited
almost exclusively in skeletal tissues (11), which are rich in
extracellular matrix (ECM) components, including collagens
and the glycosaminoglycans (GAGs) heparan sulfate and hya-
luronic acid (12–15). The mechanism of recruitment of
WT-h2m specifically to skeletal tissues is not fully under-
stood, but ECM components, such as low molecular weight
(LMW)-heparin (a GAG mimic, relevant here because this is
given to all patients undergoing renal replacement therapy),
apolipoprotein E, and collagen, have been found to enhance
WT-h2m aggregation in vitro (13, 16 –18). Amyloid fibrils
have also been found associated with collagen fibrils in ex vivo
deposits from DRA patients (13), and monomers of both
WT-h2m and its natural proteolytic product, N6-h2m,
which lacks the N-terminal six amino acids, have been shown to
have weak (KD: 4.1  104 M and 4.9  106 M, respectively
(15)) affinities for collagen I at the pathophysiologic pH of 6.4
(12). Despite this evidence of the importance of LMW-heparin
and collagen in amyloid formation, the mechanism(s) by which
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interactions with the reagents affect aggregation of WT-h2m
and N6-h2m remain unclear.
Compared with the intransigence of WT-h2m to form amy-
loid fibrils at pH 6 –7 (19, 20), N6-h2m readily forms amyloid
at these pH values in vitro (21, 22). N6-h2m comprises 30%
of the h2m present in DRA deposits (21, 23) and contains a
nonnative trans-X-P32, a prerequisite for amyloid formation
(22, 24) that is retained in the amyloid fibril structure itself (25).
Weak interactions between the apical loops of N6-h2m and
WT-h2m have been shown to promote amyloid formation
of the normally innocuous WT-h2m (26, 27), suggesting a
potential role of N6-h2m in initiating fibril assembly of
the WT protein. How N6-h2m, collagen, and LMW-hep-
arin together influence amyloid formation of WT-h2m,
however, has remained unclear.
Here we used detailed analysis of the kinetics of amyloid for-
mation to determine the role of collagen I, LMW-heparin, and
N6-h2m and their mixtures on amyloid fibril formation of
WT-h2m. The results reveal that LMW-heparin and collagen
I influence multiple phases of WT-h2m amyloid formation,
including initiation, elongation, and secondary nucleation
processes. Additionally, we found that the effects of collagen I
on amyloid formation depend on whether fibril growth of
WT-h2m is self-seeded or cross-seeded by N6-h2m fibrils.
Overall, the results shed new light on the mechanisms by which
biologically relevant factors influence WT-h2m amyloid
assembly. More generally, they reveal how the local environ-
ment can have a dramatic effect in defining the rate and mech-
anisms of protein assembly into amyloid.
Results
LMW-heparin and collagen I have a synergistic effect in the
initiation of amyloid formation of WT-h2m
The hallmark of DRA is formation of proteinaceous deposits
comprised of WT-h2m and N6-h2m in the ECM-rich joint
spaces (3). Because native WT-h2m does not form amyloid at
neutral pH or at the slightly acidified pH (pH 6.2) in affected
joints (18) unless co-solvents or copper ions are added (13,
16 –19, 28 –32) (Fig. 1A), we investigated how collagen I that is
found in the ECM and GAGs (represented by LMW-heparin)
affect the kinetics of aggregation of WT-h2m. Previous studies
have demonstrated a role of these components in h2m amy-
loid assembly (13, 15, 17, 18, 33), but the precise mechanism(s)
by which they affect aggregation, and the possible synergy
between these different components, remained unclear. Using
the enhancement of thioflavin T (ThT) fluorescence as a probe
of amyloid formation, measurement of the resulting fibril
growth kinetics showed that LMW-heparin (0.1 mg/ml)
induces fibril formation of WT-h2m (0.47 mg/ml) within 30
h, resulting in the formation of long, straight fibrils typical of
amyloid (Fig. 1, A and B). By contrast, collagen I did not induce
amyloid formation in the absence of LMW-heparin over the
time scale measured here (Fig. 1, C and D) (note, however, that
collagen can promote amyloid fibril formation over much lon-
ger time scales, as previously reported (13)). The addition of
both components revealed that collagen I modulates the kinet-
ics of LMW-heparin– driven WT-h2m fibril formation in a
complex manner (Fig. 1, E and F). At low concentrations (0.03–
0.12 mg/ml), collagen I accelerates LMW-heparin–induced
aggregation of WT-h2m, decreasing the lag time relative to
the effect of LMW-heparin alone (Fig. 1E, light green colors,
compared with Fig. 1A, blue). However, the addition of higher
concentrations of collagen I (0.47 mg/ml) in the presence of
LMW-heparin retards fibril formation by increasing the lag
time (Fig. 1E, dark green colors; see also Fig. S1A). Enhancement
of WT-h2m amyloid formation by collagen I is consistent with
previous results, which have shown that collagen I alone can
induce aggregation of WT-h2m (13). WT-h2m has also been
shown to bind to both collagen I and LMW-heparin (12, 14, 15,
18). At high concentrations of collagen I, we assume that com-
petition between collagen I and LMW-heparin binding to each
other (KD: 7.9  108 M) (34), and binding to WT-h2m may
reduce the availability of these components to interact with
WT-h2m slowing its aggregation. Sequestration of WT-h2m
nuclei/aggregates on the surface of the collagen I fibrils, which
would be favored at high concentrations of collagen I, could
also disfavor amyloid formation (see below) and contribute to
the complex dose-dependent behavior observed.
Role of the collagen sequence and conformation in
LMW-heparin–induced aggregation of WT-h2m
Collagen I can adopt a hierarchy of structures within the
ECM (Fig. 2A). The canonical collagenous sequence consists of
Gly-Xaa-Yaa triplets, where Xaa and Yaa can be any amino acid
but are most often Pro and hydroxyproline (Hyp/O), respec-
tively. Single collagen polypeptide chains fold into polyproline
type II helices. Three such chains then twist together to form a
triple helix that is stabilized by a network of interchain hydro-
gen bonds between Gly and Xaa of a neighboring chain (35).
The triple helices further self-assemble into higher order fibrils.
To determine the effects of collagen sequence and conforma-
tion on the aggregation kinetics of WT-h2m, the kinetics of
LMW-heparin–induced aggregation were monitored in the
presence of two different collagen mimetic peptides (CMPs), as
well as denatured full-length collagen I. The CMP, Ac-(Pro-
Hyp-Gly)10-GY-NH2 (named POG10), forms a stable triple
helix conformation without additional native sequence frag-
ments (36). However, this peptide does not form intermolecu-
lar interactions required to proceed to collagen fibril formation.
Removal of only one Gly from the middle POG repeat (named
Gly) disrupts the triple helix conformation (37, 38). By con-
trast with the complex effects of collagen I fibrils on the lag time
of LMW-heparin–induced aggregation of WT-h2m (Fig. 1E),
incubation of WT-h2m monomers (0.47 mg/ml) with up to 1
mg/ml POG10 or Gly peptide, in the presence of 0.1 mg/ml
LMW-heparin did not significantly affect the lag time of fibril
formation relative to the lag time in the absence of peptide (Fig.
2, B, D, and E, and Fig. S1, A, B, and D). Full-length collagen I
denatured into single chains also had no significant effect on
the lag time of aggregation (Fig. 2, C and E, and Fig. S1C).
Hence, adoption of a triple helical collagen structure with a
native sequence is required for collagen I to modulate the rate
of LMW-heparin–induced WT-h2m aggregation, highlight-
ing the specificity between the different surfaces involved in
amyloid assembly.
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Surface-mediated aggregation of WT-h2m is protected by
collagen I
To determine whether a stable complex is formed between
WT-h2m monomer and/or fibrils and collagen I, samples
were taken at different times during aggregation in the presence
or absence of 0.1 mg/ml LMW-heparin, added to collagen I (1.0
mg/ml), and pelleted 10 min later by centrifugation at 5000  g
(see “Experimental procedures”). At this low centrifugation
speed, only collagen I fibrils sediment, whereas WT-h2m
(monomers, oligomers, and fibrils) remain in the supernatant.
Whether WT-h2m monomers/small oligomers and/or fibrils
bind collagen I was then determined by monitoring the band
intensity of WT-h2m that pelleted with collagen I on an SDS-
PAGE gel. These experiments showed that WT-h2m co-pre-
cipitates with collagen I fibrils only after an incubation time of
35 h (Fig. 3, A–C) (approximately the t50 of aggregation in the
presence of 0.1 mg/ml LMW-heparin (Fig. 1A)). A higher
extent of co-precipitation was observed after 85 h, by which
time WT-h2m amyloid formation has reached completion in
the presence of LMW-heparin (Figs. 1A and 3, A and C). These
results show that the fibrillar form of WT-h2m interacts with
collagen I fibrils most tightly, whereas species formed in the lag
Figure 1. A, amyloid fibril formation of WT-h2m (40 M) in the absence (purple) or presence (blue) of 0. 1 mg/ml LMW-heparin. B, negative stain TEM at the end
of the aggregation reaction (80 h) for WT-h2m in the presence of 0.1 mg/ml LMW-heparin. C, effect of collagen I on WT-h2m aggregation in the absence of
LMW-heparin. Collagen I concentrations are indicated in the panel in mg/ml. D, negative stain TEM of the sample at 1 mg/ml collagen after 80 h of incubation.
E, effect of collagen I on WT-h2m aggregation in the presence of 0.1 mg/ml LMW-heparin. For each condition, a single ThT fluorescence (Norm. ThT fluoresc.)
trace representative of the mean aggregation kinetics taken over at least three replicate experiments with three samples in each is shown (see also Fig. S1). F,
representative negative stain TEM of the end point of the aggregation process in the presence of 1 mg/ml collagen I and 0.1 mg/ml LMW-heparin. Scale bar in
all TEM panels indicates 100 nm. Note the schematic drawings used to annotate the different reagents present in different experiments (WT-h2m (purple),
LMW-heparin (gray), and collagen I fibrils (yellow/red bundle)). These symbols are used throughout the manuscript to denote the additives included in each
experiment.
Extracellular matrix modulates 2m amyloid formation






















time appear not to bind collagen I tightly, at least at the detec-
tion limit of these experiments. Consistent with these results,
interactions between WT-h2m monomers and LMW-heparin
or collagen I were found to be weak as assessed by 1H-15N het-
eronuclear single quantum coherence NMR spectra. This was
assessed by 1 h co-incubation of 80 M 15N-WT-h2m with 0.2
mg/ml LMW-heparin and/or 2 mg/ml collagen I and measure-
ment of the chemical shifts of backbone resonances. No signif-
icant chemical shift perturbations (or linewidth) were observed
in these experiments (Fig. S2), suggesting that these interac-
tions are too weak to detect by these methods under the condi-
tions employed.
Because WT-h2m fibrils and collagen I were shown to
interact by the co-pelleting assay, we next analyzed the effect of
collagen I on seeded growth of WT-h2m fibrils (using
WT-h2m fibril seeds produced in the presence of LMW-hep-
arin (see “Experimental procedures”)). As expected, the addi-
tion of WT-h2m seeds (5–30%, v/v) enhances the rate of
formation of WT-h2m fibrils, dependent on the seed concen-
tration (Fig. 4A). Note that under these quiescent conditions
and without seeds, no fibrils form (22, 24, 26). Interestingly, a
biphasic curve is generated in the presence of fibril seeds, with
the first (relatively small) increase in ThT fluorescence inten-
sity occurring in the first 2 h (Fig. 4, A and inset). This phase
presumably monitors the elongation of fibril ends by WT-h2m
monomers. The addition of 1 mg/ml collagen I does not affect
this phase (Fig. 4B). By contrast, the second phase, with larger
ThT amplitude (Fig. 4A), is significantly retarded by the addi-
tion of 1 mg/ml collagen I (Fig. 4B and Fig. S3). In the presence
of low concentrations (5%, v/v) of seeds and under quiescent
conditions, these fibril-mediated interactions are the dominant
processes of fibril formation. Hence, in these conditions, the
interaction of collagen I with WT-h2m fibrils, observed by
co-precipitation (Fig. 3A), protects against fibril surface-medi-
ated growth of WT-h2m amyloid by masking the fibril surface.
The specificity of collagen I for WT-h2m fibrils was next
probed by monitoring the effect of collagen I on reactions in
which preformed seeds of N6-h2m were used to cross-seed
amyloid formation of WT-h2m monomers (Fig. 4, C and D).
WT-h2m and 6-h2m are known to co-aggregate (13, 18,
23), forming fibrils of a different morphology in vitro than those
formed by each protein alone (27). The results showed that the
Figure 2. The effect of CMPs and denatured collagen chains on LMW-heparin–induced WT-h2m fibril formation. A, schematic of collagen hierarchical
conformations, from the primary amino acid sequence, single-chain polyproline type II helix, triple helix of three single chains, and higher order fibrils. B–D,
LMW-heparin–induced aggregation kinetics of WT-h2m (40 M) in the presence of POG10 peptide (which forms a stable collagen triple helix; B), collagen I in
the single chain form (C), and Gly peptide (which does not form a stable triple helix; D). The concentration of the peptides added is indicated by color in the
inset. All traces were obtained with 0.1 mg/ml LMW-heparin. Negative stain TEM micrographs of the end points are shown as an inset for each condition. Scale
bar, 100 nm. E, box plot of the lag time for the WT-h2m aggregation in the presence or absence of 1 mg/ml collagen I fibrils (data taken from Fig. 1E), denatured
collagen, or CMPs. WT, WT-h2m alone (no collagen or CMPs added); FIBRIL, WT-h2m plus collagen I fibrils; POG, WT-h2m plus POG10 peptide; SC, WT-h2m
plus single chain collagen I; GLY, WT-h2m plus Gly peptide. The data are representative of three replicate experiments, with three samples in each. Asterisk
denotes p  0.002. Norm. ThT fluoresc., normal ThT fluorescence.
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effect of collagen I on the seeded aggregation of WT-h2m is
highly dependent on the identity of the seeds added. The addi-
tion of 6-h2m seeds to WT-h2m monomers also results in
biphasic fibril growth curves (Fig. 4C). However, the rate of the
initial phase is slower under all conditions for the cross-seeded
reactions compared with the self-seeded reactions (Fig. S3A).
Most notably, the secondary process, which occurs after rapid
fibril elongation, is much less affected by collagen I in the cross-
seeded reactions than when self-seeded (Fig. 4, compare B and
D; see also Fig. S3B). Thus, the interference of collagen I with
surface-mediated growth of WT-h2m fibrils depends on the
morphology of the h2m fibril seeds, which differ when self-
seeded and cross-seeded by 6-h2m (27).
LMW-heparin promotes assembly of WT-h2m fibrils in both
self-seeded and cross-seeded reactions
Finally, the effect of LMW-heparin on fibril formation of
WT-h2m was monitored in seeded reactions to determine
whether the addition of this GAG can outcompete the effect of
collagen I on aggregation. When mixed, LMW-heparin is able
to rescue the inhibitory effect of collagen I on secondary pro-
cesses whether the reaction is self- or cross-seeded (Fig. 5, A–D,
and Fig. S3). Thus, collagen I and LMW-heparin have different
effects on WT-h2m aggregation at multiple phases of fibrilla-
tion. Collagen I acts primarily on the secondary surface-medi-
ated growth of self-seeded fibrils and depends on whether the
reaction is self-seeded or cross-seeded (compare Fig. 4, A and B,
with Fig. 5, A and B). By contrast, LMW-heparin can enhance
growth at all stages of aggregation and is insensitive to the dis-
tinct amyloid conformations produced by self-seeding or cross-
seeding with N6-h2m.
Discussion
A detailed study of the effects of the local environment on the
course of protein aggregation is important for understanding
how amyloid formation may be initiated and substantiated in
vivo. Previous studies have shown the effects of chaperones
(39 –41), metal ions (19, 32, 42), membranes (43), trifluoroetha-
nol or SDS co-solvents (28, 29, 44), GAGs (18, 30, 45, 46), and
other natural compounds (13, 17, 47) on the formation of amy-
loid fibrils in vitro. For some of these compounds, detailed
kinetic analysis has revealed the effect of each reagent on the
different kinetic steps in aggregation, including primary nucle-
ation, elongation from fibril ends, and secondary processes
such as fibril fragmentation and secondary nucleation (39 – 41,
43, 48). Such studies can provide important information on the
role of biologically relevant and other compounds on amyloid
formation, including how the different factors may act syner-
gistically to alter the course of aggregation in an in vitro setting
(17, 30).
Here we have adopted this approach by examining the effects
of two macromolecules that are present in conditions relevant
to DRA, collagen I, and the GAG LMW-heparin. Because
WT-h2m is not prone to amyloid formation in the absence of
co-factors at pathophysiological pH and temperature, under-
standing how the molecular components of the local environ-
ment affect WT-h2m amyloid formation and impact the
kinetics of fibril formation is important for developing an
understanding of h2m amyloidogenesis in DRA. In addition,
how the biological environment affects the ability of N6-
h2m, which makes up 30% of the h2m component in DRA
plaques (21, 23), to stimulate aggregation of WT-h2m may
also shed light on how the aggregation of WT-h2m may be
initiated in vivo.
Understanding amyloid formation of WT-h2m in mech-
anistic detail in the context of the ECM in joints and cartilage
is extremely challenging, given the multicomponent compo-
sition it presents. Here, we have started to investigate aggre-
gation in this environment by determining how different
components relevant to DRA (collagen I and LMW-heparin)
impact the different kinetic stages of WT-h2m aggregation.
The studies presented show that LMW-heparin, collagen I,
and N6-h2m have different effects on the course of
WT-h2m aggregation, which compete for the different
stages of aggregate formation. First, under all conditions,
LMW-heparin is able to promote the self-assembly of
WT-h2m, decreasing the lag time and increasing the rate of
fibril formation by affecting secondary stages, whether self-
seeded or cross-seeded by N6-h2m. Previous studies have
shown that LMW-heparin binds and stabilizes WT-h2m
amyloid fibrils, whereas the nonsulfated GAG hyaluronic
acid has no effect on fibril stability or the rate of fibril for-
mation, suggesting that ionic interactions between the GAG
and WT-h2m must be involved (17). Determining the ori-
gins of molecular recognition between different species
Figure 3. A, co-pelleting of WT-h2m aggregated for different times with
collagen I fibrils with/without 0.1 mg/ml LMW-heparin. SDS-PAGE analysis of
the whole sample (w) and the pellet after sedimentation of collagen I by
low-speed centrifugation (P). Molecular mass markers with masses in kDa are
shown alongside. B, negative stain TEM micrograph of WT-h2m incubated in
the presence of 1.0 mg/ml collagen I and 0.1 mg/ml LMW-heparin for 15 h,
showing the presence of collagen I fibrils but no WT-h2m amyloid. C, as in B,
but image taken after incubation for 65 h. WT-h2m amyloid can be clearly
seen in this image alongside collagen I fibrils. The scale bar in each micro-
graph is 500 nm.
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(monomers, oligomers, and fibrils) of WT-h2m and N6-
2m and GAGs will require further exploration, for example
by varying the patterns of sulfation, the identity of the car-
bohydrate moieties that differ between GAGs, and the length
of the GAG, which have been shown previously to affect
amyloid-GAG recognition (46, 50). Analysis of the effects of
heparan sulfate, the most abundant GAG in the joint ECM,
would be particularly important for h2m, although previ-
ous studies have shown that heparan sulfate and LMW-hep-
arin have similar effects on seeded elongation of fibril growth
using WT-h2m (17).
By contrast with LMW-heparin, collagen I has a more
complex role on WT-h2m assembly into amyloid, affecting
the lag time of fibril formation and secondary growth phases
in different ways, dependent on the concentration added, the
presence of LMW-heparin, the structural organization of the
collagen added, and whether fibril growth of WT-h2m is
self-seeded or cross-seeded by N6-h2m fibrils. A decrease
in the lag time of WT-h2m assembly occurs upon addition
of low concentrations of collagen I and LMW-heparin rela-
tive to the addition of LMW-heparin alone, suggestive of one
route for the initiation of WT-h2m assembly at pathophys-
iological pH and temperature. However, at high concentra-
tions of collagen I, the lag time is extended. Collagen I fibrils
also interact strongly with WT-h2m amyloid fibrils, sup-
pressing surface-mediated growth (Fig. 6, top row) by com-
peting for interactions with the WT-h2m fibril surface.
Notably, a different fibril morphology formed by cross-seed-
ing WT-h2m with N6-h2m fibrils does not show this
marked suppression of fibril formation by collagen I (Fig. 6,
bottom row). Whether self-seeded or cross-seeded with N6
fibril seeds, LMW-heparin is able to outcompete the binding
of collagen I to WT-h2m fibrils, releasing the potential of
the amyloid fibril surface to enhance fibril formation via sec-
ondary nucleation processes. These results are consistent
with previous studies that also showed enhanced aggrega-
tion of WT-h2m in the presence of LMW-heparin (18, 24).
In addition to its role in suppressing amyloid formation,
interactions between collagen I and WT-h2m fibrils may
prevent the clearance of amyloid from the joint space, pro-
viding an explanation for the localization of DRA plaques to
joint and cartilage tissues. Other factors not investigated
here, such as the presence of chaperones and/or other pro-
teins, oxidation, glycation, or other post-translational mod-
ifications of the h2m sequence, the presence of Cu2	 ions,
and shear flow within the joint space, may also contribute to
amyloid formation (17, 19, 31, 40, 51, 52). Overall, therefore,
the results portray a marked complexity in amyloid forma-
tion in the ECM, in which a finely tuned balance of different
components (in this case collagen I, LMW-heparin, and
N6-h2m) affect the progression of h2m aggregation and
its sequestration in the joints to give a pattern of amyloid
deposition that is the hallmark of DRA.
Figure 4. The effect of collagen I fibrils on self-seeded and cross-seeded growth with WT-h2m monomers. A, aggregation kinetics of WT-h2m in the
presence of preformed WT-h2m seeds (5–30%, v/v). The inset shows an expanded plot over the first 2 h. B, as in A, but in the presence of 1 mg/ml collagen
I. C, aggregation kinetics of WT-h2m in the presence of preformed N6-h2m seeds (5–30%, v/v). The inset shows an expanded plot over the first 2 h. D, as
in C, but upon addition of 1 mg/ml of collagen I. Three replicate experiments, with three samples in each were measured. Here, a single trace representative of
the mean aggregation kinetics is shown. See also Fig. S3 for statistics. Norm. ThT fluoresc., normal ThT fluorescence.
Extracellular matrix modulates 2m amyloid formation
























WT-h2m and N6-h2m were expressed and purified as
described previously (22). For NMR experiments, 15N- and 13C-
labeled WT-h2m and N6 h2m were prepared as described
in Ref. 53.
Collagen preparation
Collagen type I (354249) from rat tail was purchased from BD
Biosciences. Collagen was diluted to 3 mg/ml in 0.1 M acetic
acid. Before use, it was dialyzed into 50 mM MES, 120 mM NaCl
at pH 6.2. For preparation of collagen I fibrils, the dialyzed
collagen was incubated at 37 °C for 1 h. For preparation of col-
lagen single chains, the dialyzed collagen was incubated for 30
min at 70 °C. CMPs POG10 and Gly were purchased from
LifeTein and Tufts University Core facility, respectively, and
were directly diluted into 50 mM MES, 120 mM NaCl at pH 6.2
to the concentrations specified.
Formation of fibril seeds
Fibrils of WT-h2m were assembled in 50 mM MES buffer,
120 mM NaCl at pH 6.2 in the presence of 0.1 mg/ml LMW-
heparin (Iduron) in a BMG Fluostar Optima plate reader at
37 °C at 600 rpm. The fibrils were sonicated for 1 min, distrib-
uted in aliquots, and frozen in liquid nitrogen. The size of the
seeds was determined using negative stain transmission EM
(TEM).
Kinetic measurement of aggregation
WT-h2m and N6-h2m fibrils were assembled in 50 mM
MES buffer, 120 mM NaCl at pH 6.2. Fibril growth was per-
formed in a BMG Fluostar Optima plate reader at 37 °C at 600
Figure 5. The effect of LMW-heparin on self-seeded and cross-seeded growth with WT-h2m monomers. A, aggregation kinetics of WT-h2m in the
presence of preformed WT-h2m seeds (5–30%, v/v) and 0.1 mg/ml LMW-heparin. The inset shows an expansion of the first 2 h. B, as in A, but in the presence
of 0.1 mg/ml LMW-heparin and 1 mg/ml collagen I. C, aggregation kinetics of WT-h2m in the presence of preformed N6-h2m seeds (5–30%, v/v) in the
presence of 0.1 mg/ml LMW-heparin. The inset shows an expansion of the first 2 h. D, as in C, but in the presence of 0.1 mg/ml LMW-heparin and 1 mg/ml
collagen I. Three replicate experiments, with three samples in each were acquired. See also Fig. S3. Norm. ThT fluoresc., normal ThT fluorescence.
Figure 6. Schematic of the effect of ECM components on seeded
WT-h2m aggregation. Top row, WT-h2m forms amyloid through self-
seeded fibril growth. A secondary phase, fibril surface-mediated growth is
enhanced by LMW-heparin and a co-mixture of LMW-heparin and collagen I
but is suppressed by collagen alone. Bottom row, cross-seeding WT-h2m
monomer with N6-h2m seeds forms fibrils with a different conforma-
tion(27). The fibril surface mediated growth of these fibrils is also enhanced
by LMW-heparin and the LMW-heparin and collagen I co-mixture but is not
affected by collagen I alone.
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rpm (or quiescently in the case of seeded reactions). A final
concentration of 10 M ThT (Sigma) and 40 M 2m was used.
When required, seeds (5–30%, v/v) were added. The fibril yield
was measured by centrifuging 50 l of the end points at
14,000  g, where amyloid fibrils are found in the pellet and
soluble material remains in the supernatant and can be quanti-
fied spectrophotometrically.
Determination of the lag time of fibril growth
The lag times of fibril growth under different conditions were
determined by fitting a tangent to the curve at the midpoint of
the elongation phase and extrapolating this time to the baseline
signal in the lag phase. The intersection point of these two lines
was considered the lag time.
Determination of the elongation rate and the half-time of
kinetics in the presence of seeds
ThT fluorescence curves were normalized to the final time
point where 100% of the protein was converted to fibrils. In
cases where this was not the case, and therefore there was no
plateau in the fluorescence curves (such as in Fig. 4, B and D),
the ThT signal was normalized to the corresponding value in
the presence of LMW-heparin (Fig. 5, B and D) where the fibril
yield was 100%. The observed elongation rate was calculated by
fitting straight lines to the ThT fluorescence curves in the first
hour of the normalized aggregation kinetics divided by the con-
centration of seeds. The t50 is the time taken to reach 50% of the
maximal ThT fluorescence.
Collagen co-precipitation
40 M WT-h2m (in the presence/absence of 0.1 mg/ml
LMW-heparin) was incubated at 37 °C at 600 rpm in a BMG
Fluostar Optima plate reader. At different time points, 40-l
aliquots were taken and mixed with 1 mg/ml of collagen I fibrils
and incubated for 10 min. The sample was centrifuged at
5000  g for 10 min. Samples in the absence of LMW-heparin
were used as a control. The pellet was washed once with the
incubation buffer, and the centrifugation step was repeated.
The pellet and the supernatant were then separately analyzed
using 15% (w/v) polyacrylamide Tris-Tricine gels. The gels
were stained with Coomassie Instant Blue (Expedeon).
NMR spectroscopy
Samples of 15N-labeled protein (40 – 80 M) in 50 mM MES
buffer containing 120 mM NaCl, pH 6.2, 90% (v/v) H2O, 10%
(v/v) D2O were used for NMR experiments. 1H-15N heteronu-
clear single quantum coherence spectra were collected in a Var-
ian INOVA NMR spectrometer performing at 600 MHz and
were processed in NMRPipe and analyzed using programs
available in CCPNMR analysis (49, 54).
EM
At the end of fibril assembly, 10 l of sample were applied to
carbon-coated EM grids. The grids were then carefully dried
with filter paper before samples were negatively stained by the
addition of 10 l of 2% (w/v) uranyl acetate. Micrographs were
recorded on a JEOL JEM-1400 electron microscope.
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